Jace Yawnick was diagnosed with primary mediastinal B-cell non-Hodgkin lymphoma in Jan. 2024 at 25 years old. However, ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and mediastinal large B-cell lymphoma. GC and non-GC DLBCL differ with respect to the cell ...
Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
The treatment will be available in the third line setting for all adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...
The mediastinal mass ... 4,6 and not a thymic lymphoma. Histologically, the positive staining of the atypical epithelioid cells with the epithelial cell marker enabled a definitive diagnosis ...